Loading…

Effect of bromazepam versus placebo on inhibition and waiting capacity in young women with traits of anxiety

Summary— The effect of 3 dosages of bromazepam administered as single oral doses (1.5, 3 and 6 mg) on anxious inhibition phenomena was studied in a population of 16 young women (18–30 years) with anxiety‐traits, selected on the criteria of Cattell's anxiety scale supported by two personality in...

Full description

Saved in:
Bibliographic Details
Published in:Fundamental & clinical pharmacology 1998-01, Vol.12 (4), p.463-467
Main Authors: Schuck, S, Allain, H, Gandon, J-M, Patat, A, Millet, V, Le Coz, F
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4883-222e8d2e061bd781d9ed9b52c03cbd3d0a938fdf4f7e3d194e241339f378fca03
cites cdi_FETCH-LOGICAL-c4883-222e8d2e061bd781d9ed9b52c03cbd3d0a938fdf4f7e3d194e241339f378fca03
container_end_page 467
container_issue 4
container_start_page 463
container_title Fundamental & clinical pharmacology
container_volume 12
creator Schuck, S
Allain, H
Gandon, J-M
Patat, A
Millet, V
Le Coz, F
description Summary— The effect of 3 dosages of bromazepam administered as single oral doses (1.5, 3 and 6 mg) on anxious inhibition phenomena was studied in a population of 16 young women (18–30 years) with anxiety‐traits, selected on the criteria of Cattell's anxiety scale supported by two personality inventory (Eysenck's, MMPI). A double‐blind, placebo study design was chosen. The main assessment criteria were based on the go/no‐go test (Logan's procedure), slow response rate (SRR) and a task of forced or unforced decision (use of the CFF). Attentional processes and declarative memory were analyzed as secondary criteria. None of the three dosages modified inhibition or acting‐out. Sustained attention was reduced with 1.5 mg and 6 mg, as was memory performance with 3 and 6 mg, 3.5 h after drug administration. In contradistinction with studies carried out in healthy volunteers or with other benzodiazepine compounds, bromazepam at single low dosages does not modify inhibition capacity in these subjects with traits of anxiety, in this particular procedure.
doi_str_mv 10.1111/j.1472-8206.1998.tb00973.x
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73864584</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73864584</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4883-222e8d2e061bd781d9ed9b52c03cbd3d0a938fdf4f7e3d194e241339f378fca03</originalsourceid><addsrcrecordid>eNqVkF2L1DAYhYMo67j6E4Qg4l1rPtom8UKQYXd2cVARxcuQ5sPN2C-T1pn6602ZMvfmJoec5z1vOAC8wijH6bw95LhgJOMEVTkWgudjjZBgND89ApuL9RhsEKtYRgXHT8GzGA8IYYZwdQWuBMOJwxvQ3Dhn9Qh7B-vQt-qvHVQL_9gQpwiHRmlb97DvoO8efO1Hn6TqDDyqpLufUKtBaT_OyYdzP6WXY9_aDh79-ADHkKi4RKvu5O04PwdPnGqifbHe1-D77c237V22_7y7337YZ7rgnGaEEMsNsajCtWEcG2GNqEuiEdW1oQYpQbkzrnDMUoNFYUmBKRWOMu60QvQavDnnDqH_Pdk4ytZHbZtGdbafomSUV0XJiwS-O4M69DEG6-QQfKvCLDGSS9XyIJc-5dKnXKqWa9XylIZfrlumurXmMrp2m_zXq6-iVo0LqtM-XjBCy5KTKmHvz9jRN3b-jw_I2-2XJFJAdg7wcbSnS4AKv2TFKCvlj087-ZF83RPGdhLTf_I9q_I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73864584</pqid></control><display><type>article</type><title>Effect of bromazepam versus placebo on inhibition and waiting capacity in young women with traits of anxiety</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Schuck, S ; Allain, H ; Gandon, J-M ; Patat, A ; Millet, V ; Le Coz, F</creator><creatorcontrib>Schuck, S ; Allain, H ; Gandon, J-M ; Patat, A ; Millet, V ; Le Coz, F</creatorcontrib><description>Summary— The effect of 3 dosages of bromazepam administered as single oral doses (1.5, 3 and 6 mg) on anxious inhibition phenomena was studied in a population of 16 young women (18–30 years) with anxiety‐traits, selected on the criteria of Cattell's anxiety scale supported by two personality inventory (Eysenck's, MMPI). A double‐blind, placebo study design was chosen. The main assessment criteria were based on the go/no‐go test (Logan's procedure), slow response rate (SRR) and a task of forced or unforced decision (use of the CFF). Attentional processes and declarative memory were analyzed as secondary criteria. None of the three dosages modified inhibition or acting‐out. Sustained attention was reduced with 1.5 mg and 6 mg, as was memory performance with 3 and 6 mg, 3.5 h after drug administration. In contradistinction with studies carried out in healthy volunteers or with other benzodiazepine compounds, bromazepam at single low dosages does not modify inhibition capacity in these subjects with traits of anxiety, in this particular procedure.</description><identifier>ISSN: 0767-3981</identifier><identifier>EISSN: 1472-8206</identifier><identifier>DOI: 10.1111/j.1472-8206.1998.tb00973.x</identifier><identifier>PMID: 9711471</identifier><identifier>CODEN: FCPHEZ</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Administration, Oral ; Adolescent ; Adult ; Anti-Anxiety Agents - pharmacology ; Anti-Anxiety Agents - therapeutic use ; anxiety ; Anxiety - drug therapy ; Attention - drug effects ; benzodiazepine ; Biological and medical sciences ; bromazepam ; Bromazepam - pharmacology ; Bromazepam - therapeutic use ; cognition ; Double-Blind Method ; Female ; Humans ; inhibition ; Medical sciences ; memory ; Memory - drug effects ; Neuropharmacology ; Pharmacology. Drug treatments ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychometrics ; Psychopharmacology</subject><ispartof>Fundamental &amp; clinical pharmacology, 1998-01, Vol.12 (4), p.463-467</ispartof><rights>1998 Société Française de Pharmacologie et de Thérapeutique</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4883-222e8d2e061bd781d9ed9b52c03cbd3d0a938fdf4f7e3d194e241339f378fca03</citedby><cites>FETCH-LOGICAL-c4883-222e8d2e061bd781d9ed9b52c03cbd3d0a938fdf4f7e3d194e241339f378fca03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2355826$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9711471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schuck, S</creatorcontrib><creatorcontrib>Allain, H</creatorcontrib><creatorcontrib>Gandon, J-M</creatorcontrib><creatorcontrib>Patat, A</creatorcontrib><creatorcontrib>Millet, V</creatorcontrib><creatorcontrib>Le Coz, F</creatorcontrib><title>Effect of bromazepam versus placebo on inhibition and waiting capacity in young women with traits of anxiety</title><title>Fundamental &amp; clinical pharmacology</title><addtitle>Fundam Clin Pharmacol</addtitle><description>Summary— The effect of 3 dosages of bromazepam administered as single oral doses (1.5, 3 and 6 mg) on anxious inhibition phenomena was studied in a population of 16 young women (18–30 years) with anxiety‐traits, selected on the criteria of Cattell's anxiety scale supported by two personality inventory (Eysenck's, MMPI). A double‐blind, placebo study design was chosen. The main assessment criteria were based on the go/no‐go test (Logan's procedure), slow response rate (SRR) and a task of forced or unforced decision (use of the CFF). Attentional processes and declarative memory were analyzed as secondary criteria. None of the three dosages modified inhibition or acting‐out. Sustained attention was reduced with 1.5 mg and 6 mg, as was memory performance with 3 and 6 mg, 3.5 h after drug administration. In contradistinction with studies carried out in healthy volunteers or with other benzodiazepine compounds, bromazepam at single low dosages does not modify inhibition capacity in these subjects with traits of anxiety, in this particular procedure.</description><subject>Administration, Oral</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Anti-Anxiety Agents - pharmacology</subject><subject>Anti-Anxiety Agents - therapeutic use</subject><subject>anxiety</subject><subject>Anxiety - drug therapy</subject><subject>Attention - drug effects</subject><subject>benzodiazepine</subject><subject>Biological and medical sciences</subject><subject>bromazepam</subject><subject>Bromazepam - pharmacology</subject><subject>Bromazepam - therapeutic use</subject><subject>cognition</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>inhibition</subject><subject>Medical sciences</subject><subject>memory</subject><subject>Memory - drug effects</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychometrics</subject><subject>Psychopharmacology</subject><issn>0767-3981</issn><issn>1472-8206</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNqVkF2L1DAYhYMo67j6E4Qg4l1rPtom8UKQYXd2cVARxcuQ5sPN2C-T1pn6602ZMvfmJoec5z1vOAC8wijH6bw95LhgJOMEVTkWgudjjZBgND89ApuL9RhsEKtYRgXHT8GzGA8IYYZwdQWuBMOJwxvQ3Dhn9Qh7B-vQt-qvHVQL_9gQpwiHRmlb97DvoO8efO1Hn6TqDDyqpLufUKtBaT_OyYdzP6WXY9_aDh79-ADHkKi4RKvu5O04PwdPnGqifbHe1-D77c237V22_7y7337YZ7rgnGaEEMsNsajCtWEcG2GNqEuiEdW1oQYpQbkzrnDMUoNFYUmBKRWOMu60QvQavDnnDqH_Pdk4ytZHbZtGdbafomSUV0XJiwS-O4M69DEG6-QQfKvCLDGSS9XyIJc-5dKnXKqWa9XylIZfrlumurXmMrp2m_zXq6-iVo0LqtM-XjBCy5KTKmHvz9jRN3b-jw_I2-2XJFJAdg7wcbSnS4AKv2TFKCvlj087-ZF83RPGdhLTf_I9q_I</recordid><startdate>19980101</startdate><enddate>19980101</enddate><creator>Schuck, S</creator><creator>Allain, H</creator><creator>Gandon, J-M</creator><creator>Patat, A</creator><creator>Millet, V</creator><creator>Le Coz, F</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980101</creationdate><title>Effect of bromazepam versus placebo on inhibition and waiting capacity in young women with traits of anxiety</title><author>Schuck, S ; Allain, H ; Gandon, J-M ; Patat, A ; Millet, V ; Le Coz, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4883-222e8d2e061bd781d9ed9b52c03cbd3d0a938fdf4f7e3d194e241339f378fca03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Administration, Oral</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Anti-Anxiety Agents - pharmacology</topic><topic>Anti-Anxiety Agents - therapeutic use</topic><topic>anxiety</topic><topic>Anxiety - drug therapy</topic><topic>Attention - drug effects</topic><topic>benzodiazepine</topic><topic>Biological and medical sciences</topic><topic>bromazepam</topic><topic>Bromazepam - pharmacology</topic><topic>Bromazepam - therapeutic use</topic><topic>cognition</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>inhibition</topic><topic>Medical sciences</topic><topic>memory</topic><topic>Memory - drug effects</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychometrics</topic><topic>Psychopharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schuck, S</creatorcontrib><creatorcontrib>Allain, H</creatorcontrib><creatorcontrib>Gandon, J-M</creatorcontrib><creatorcontrib>Patat, A</creatorcontrib><creatorcontrib>Millet, V</creatorcontrib><creatorcontrib>Le Coz, F</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Fundamental &amp; clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schuck, S</au><au>Allain, H</au><au>Gandon, J-M</au><au>Patat, A</au><au>Millet, V</au><au>Le Coz, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of bromazepam versus placebo on inhibition and waiting capacity in young women with traits of anxiety</atitle><jtitle>Fundamental &amp; clinical pharmacology</jtitle><addtitle>Fundam Clin Pharmacol</addtitle><date>1998-01-01</date><risdate>1998</risdate><volume>12</volume><issue>4</issue><spage>463</spage><epage>467</epage><pages>463-467</pages><issn>0767-3981</issn><eissn>1472-8206</eissn><coden>FCPHEZ</coden><abstract>Summary— The effect of 3 dosages of bromazepam administered as single oral doses (1.5, 3 and 6 mg) on anxious inhibition phenomena was studied in a population of 16 young women (18–30 years) with anxiety‐traits, selected on the criteria of Cattell's anxiety scale supported by two personality inventory (Eysenck's, MMPI). A double‐blind, placebo study design was chosen. The main assessment criteria were based on the go/no‐go test (Logan's procedure), slow response rate (SRR) and a task of forced or unforced decision (use of the CFF). Attentional processes and declarative memory were analyzed as secondary criteria. None of the three dosages modified inhibition or acting‐out. Sustained attention was reduced with 1.5 mg and 6 mg, as was memory performance with 3 and 6 mg, 3.5 h after drug administration. In contradistinction with studies carried out in healthy volunteers or with other benzodiazepine compounds, bromazepam at single low dosages does not modify inhibition capacity in these subjects with traits of anxiety, in this particular procedure.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>9711471</pmid><doi>10.1111/j.1472-8206.1998.tb00973.x</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0767-3981
ispartof Fundamental & clinical pharmacology, 1998-01, Vol.12 (4), p.463-467
issn 0767-3981
1472-8206
language eng
recordid cdi_proquest_miscellaneous_73864584
source Wiley-Blackwell Read & Publish Collection
subjects Administration, Oral
Adolescent
Adult
Anti-Anxiety Agents - pharmacology
Anti-Anxiety Agents - therapeutic use
anxiety
Anxiety - drug therapy
Attention - drug effects
benzodiazepine
Biological and medical sciences
bromazepam
Bromazepam - pharmacology
Bromazepam - therapeutic use
cognition
Double-Blind Method
Female
Humans
inhibition
Medical sciences
memory
Memory - drug effects
Neuropharmacology
Pharmacology. Drug treatments
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychometrics
Psychopharmacology
title Effect of bromazepam versus placebo on inhibition and waiting capacity in young women with traits of anxiety
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T21%3A36%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20bromazepam%20versus%20placebo%20on%20inhibition%20and%20waiting%20capacity%20in%20young%20women%20with%20traits%20of%20anxiety&rft.jtitle=Fundamental%20&%20clinical%20pharmacology&rft.au=Schuck,%20S&rft.date=1998-01-01&rft.volume=12&rft.issue=4&rft.spage=463&rft.epage=467&rft.pages=463-467&rft.issn=0767-3981&rft.eissn=1472-8206&rft.coden=FCPHEZ&rft_id=info:doi/10.1111/j.1472-8206.1998.tb00973.x&rft_dat=%3Cproquest_cross%3E73864584%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4883-222e8d2e061bd781d9ed9b52c03cbd3d0a938fdf4f7e3d194e241339f378fca03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=73864584&rft_id=info:pmid/9711471&rfr_iscdi=true